Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

International uniform response criteria for multiple myeloma

Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908

Fitness and frailty in myeloma

Pawlyn, C., Khan, A., & Freeman, C. L. L. (2022) · Hematology · doi:10.1182/hematology.2022000346 · Cited by 16

Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom

Mohty, M., Knauf, W. U., Romanus, D., Corman, S. L., Verleger, K., Kwon, Y., Cherepanov, D., Cambron‐Mellott, M. J., Vikis, H. G., Gonzalez, F., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13439 · Cited by 15

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

Mina, R., Bonello, F., Petrucci, M. T., Liberati, A. M., Conticello, C., Ballanti, S., Musto, P., Olivieri, A., Benevolo, G., Capra, A., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.243428 · Cited by 14

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups

Scott, E. C., Hari, P., Kumar, S., Fraser, R. A., Dávila, O., Shah, N. D., Gale, R. P., Díaz, M. Á., Agrawal, V., Cornell, R. F., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.08.013 · Cited by 14

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial

Mina, R., Falcone, A. P., Bringhen, S., Liberati, A. M., Pescosta, N., Petrucci, M. T., Ciccone, G., Capra, A., Patriarca, F. F., Rota‐Scalabrini, D., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00590-5 · Cited by 14

Maintenance and continuous therapy for multiple myeloma

Richardson, P. G. G., Laubach, J. P., Gandolfi, S., Facon, T. T. F., Weisel, K. C., & O’Gorman, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1490181 · Cited by 13

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Weisel, K. C., Dimopoulos, M. A., Moreau, P., Yağcı, M., Larocca, A., Kanate, A. S., Vural, F., Cascavilla, N., Basu, S., Johnson, P. R. E., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1747066 · Cited by 13

New Strategies for the Treatment of Older Myeloma Patients

Larocca, A., Cani, L., Bertuglia, G., Bruno, B., & Bringhen, S. (2023) · Cancers · doi:10.3390/cancers15102693 · Cited by 14

Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options

Mettias, S., ElSayed, A., Moore, J., & Berenson, J. R. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01122-4 · Cited by 12

Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute

Okello, C. D., Mulumba, Y., Omoding, A., Ddungu, H., Welch, K., Thompson, C. L., Cowan, A. J., Cooney, M. M., & Orem, J. (2021) · African Health Sciences · doi:10.4314/ahs.v21i1.11 · Cited by 12

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

Weisel, K. C., Ludwig, H., Rieth, A., Lebioda, A., & Goldschmidt, H. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02307-5 · Cited by 12

Moving Toward Continuous Therapy in Multiple Myeloma

Bonello, F., Cetani, G., Bertamini, L., Gay, F., & Larocca, A. (2019) · Clinical Hematology International · doi:10.2991/chi.d.191101.001 · Cited by 13

Drug resistance and minimal residual disease in multiple myeloma

Gozzetti, A., Ciofini, S., Sicuranza, A., Pacelli, P., Raspadori, D., Cencini, E., Tocci, D., & Bocchia, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.116 · Cited by 12

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

Yan, X., Xu, X. S., Weisel, K. C., Mateos, M., Sonneveld, P., Dimopoulos, M. A., Usmani, S. Z., Bahlis, N. J., Puchalski, T. A., Ukropec, J., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12836 · Cited by 11

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis

Bonello, F., Pulini, S., Ballanti, S., Gentile, M., Spada, S., Annibali, O., Omedè, P., Ronconi, S., Cangialosi, C., Podda, L., et al. (2019) · Cancers · doi:10.3390/cancers11111735 · Cited by 11

Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye

Vaxman, I., & Gertz, M. A. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1873320 · Cited by 10

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282624 · Cited by 9

Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future

Diamond, B. T., Maclachlan, K. H., Chung, D. J., Lesokhin, A. M., & Landgren, O. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101140 · Cited by 9

Newly diagnosed multiple myeloma: making sense of the menu

Costello, C. L. (2022) · Hematology · doi:10.1182/hematology.2022000404 · Cited by 11

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

Ninkovic, S., & Quach, H. (2020) · Cancers · doi:10.3390/cancers12113488 · Cited by 9

New regimens and directions in the management of newly diagnosed multiple myeloma

Bal, S., Giri, S., Godby, K. N., & Costa, L. J. (2021) · American Journal of Hematology · doi:10.1002/ajh.26080 · Cited by 9

A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma

Tang, W., Li, Y., Zou, Z., Cui, J., Wang, F., Zheng, Y., Hou, L., Pan, L., Xiang, B., Chang, H., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5228 · Cited by 8

First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium

Côté, J. A., Kotb, R. R., Bergstrom, D. J., LeBlanc, R., Mian, H. S., Othman, I., & Louzada, M. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.016 · Cited by 9

Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China

Zhuang, Z., Tian, Y., Shi, L., Zou, D., Feng, R., Tian, W.-W., Yu, H., Dong, F., Liao, A., Ma, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1028571 · Cited by 8

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study

Fabro, V. D., Giorgio, M. A. D., Leotta, V., Duminuco, A., Bellofiore, C., Markovic, U., Romano, A., Bulla, A., Pelle, A. C., Elia, F., et al. (2023) · Cancers · doi:10.3390/cancers15164036 · Cited by 8

Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens

Zamagni, E., Dhanasiri, S., Ghale, A., Moore, A., & Roussel, M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1924369 · Cited by 8

Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan

Suzuki, T., Maruyama, D., Iida, S., & Nagai, H. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac111 · Cited by 8

Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature

Huynh, L., Birsen, R., Mora, L., Couderc, A., Mitha, N., Farcet, A., Chebib, A., & Chaı̈bi, P. (2022) · Cancers · doi:10.3390/cancers14194741 · Cited by 8

Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial

Suzuki, K., Min, C., Kım, K., Lee, J., Shibayama, H., Ko, P., Huang, S., Li, S., Ding, B., Khurana, M., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03204-9 · Cited by 8

Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Segura, M. R., Caballero‐Velázquez, T., Herrera, P., Patriarca, F. F., Fanin, R., Bruno, B., Einsele, H., Nahi, H., Granell, M., López‐Corral, L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.01.026 · Cited by 8

High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies

Novellis, D. D., Scala, P., Giudice, V., & Selleri, C. (2025) · Cells · doi:10.3390/cells14110776 · Cited by 6

A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)

Dimopoulos, M. A., Cavo, M., Mateos, M., Facon, T. T. F., Heeg, B. M. S., van Beekhuizen, S., Gebregergish, S. B., Nair, S. C., Pisini, M., Lam, A., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1682571 · Cited by 7

A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results

Sessa, M., Cavazzini, F., Cavallari, M., Rigolin, G. M., & Cuneo, A. (2020) · Genes · doi:10.3390/genes11121453 · Cited by 8

Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients

Rafae, A., Ehsan, H., Wahab, A., Khan, S. I., KHAN, I. A., Ashraf, S., Ali, S., Khalid, F., Neupane, K., Valent, J. N., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103744 · Cited by 7

Front‐line treatment of multiple myeloma

Cavo, M., Tacchetti, P., & Zamagni, E. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000242 · Cited by 7

Limited treatment options in refractory multiple myeloma: promising therapeutic developments

Oriol, A., Abril, L., Ibarra, G., & Senín, A. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1708721 · Cited by 7

Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low‐Dose Dexamethasone

Li, Y., Kassir, N., Wang, X., Palmisano, M., & Zhou, S. Y. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1602 · Cited by 7

Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists

Joao, C. M., Geraldes, C., Neves, M. L., Mariz, M., & Trigo, F. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.06.002 · Cited by 7

Real-World Outcomes of Pomalidomide Therapy after Lenalidomide Induction in Relapsed/Refractory Multiple Myeloma

Mark, T. M., Falkenstein, A., & Kish, J. K. (2021) · Future Oncology · doi:10.2217/fon-2021-1176 · Cited by 7

Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: A retrospective cohort study from 2009 to 2020 in a Brazilian metropolis

Drummond, P. L. D. M., dos Santos, R. M. M., Reis, A. M. M., Malta, J. S., Silveira, L. P., da Costa, I. H. F., & de Pádua, C. A. M. (2023) · Cancer Epidemiology · doi:10.1016/j.canep.2023.102377 · Cited by 6

Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries

Abildgaard, N., Anttila, P. M., Waage, A., Rubin, K. H., Ørstavik, S., Bent‐Ennakhil, N., Gavini, F., Ma, Y., Freilich, J., & Hansson, M. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113921 · Cited by 6

Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation

Nawas, M. T., Sheng, Y., Huang, C., Andreadis, C. B., Martin, T. G., Wolf, J. L., Ai, W. Z., Kaplan, L. D., Mannis, G. N., Logan, A. C., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.09.027 · Cited by 6

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

Bringhen, S., Pour, L., Benjamin, R., Grosicki, S., Min, C., de Farias, D. L. C., Vorog, A., Labotka, R., Wang, B., Cherepanov, D., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.007 · Cited by 6

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Samaras, P., Bargetzi, M. J., Betticher, D. C., Driessen, C., Duchosal, M. A., Heim, D. A., Ketterer, N., Lerch, E., Matthes, T., Mey, U., et al. (2019) · Swiss Medical Weekly · doi:10.4414/smw.2019.20031 · Cited by 6

A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial

Bergin, K., Yuen, F., Wallington-Beddoe, C. T., Kalff, A., Sirdesai, S., Reynolds, J., & Spencer, A. G. (2021) · British Journal of Haematology · doi:10.1111/bjh.17504 · Cited by 6

A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma

Oriol, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1744432 · Cited by 6

Initial Therapeutic Approaches to Patients with Multiple Myeloma

Berbari, H. E., & Kumar, S. K. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01824-5 · Cited by 6

Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study

Visram, A., Chan, K., Seow, H. Y., Pond, G. R., Gayowsky, A., Mohyuddin, G. R., McCurdy, A. B. R., Sandhu, I., Venner, C. P., Lancman, G., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285768 · Cited by 5

Factors Increasing the Risk of Infection in Patients With Multiple Myeloma: From Biology to Prevention

Encinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 5

Global Approaches in Myeloma: Critical Trials That May Change Practice

Moreau, P., & Touzeau, C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200841 · Cited by 5

Evolution or revolution in multiple myeloma therapy and the role of the UK

Cook, G., & Morris, C. T. C. M. (2020) · British Journal of Haematology · doi:10.1111/bjh.17148 · Cited by 5

Frail Multiple Myeloma Patients Deserve More Than Just a Score

Miller, H., & Sharpley, F. A. (2023) · Hematology Reports · doi:10.3390/hematolrep15010015 · Cited by 5

Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma

Isa, R., Uoshima, N., Takahashi, R., Nakano-Akamatsu, S., Kawata, E., Kaneko, H., Shimura, K., Kamitsuji, Y., Takimoto‐Shimomura, T., Mizutani, S., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03859-9 · Cited by 5

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

Bobin, A., Gardeney, H., Sabirou, F., Gruchet, C., Lévy, A., Nsiala, L., Cailly, L., Tomowiak, C., Diaz, J. M. T., Guidez, S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00676 · Cited by 5

Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

Ozaki, S., Handa, H., Koiso, H., Saitoh, T., Sunami, K., Ishida, T., Suzuki, K., Narita, T., Iida, S., Nakamura, Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03668-6 · Cited by 5

Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence

Davidson, J., Kumar, A. D., Patel, A. R., Chen, I. Y., Butte, A. J., & Zack, T. I. (2026) · Cancers · doi:10.3390/cancers18040669 · Cited by 4

Secondary Malignancies in Multiple Myeloma in Korean Patients: A Nationwide Population-Based Study

Park, B., Lee, E., Yoon, J., Park, Y. S., & Eom, H. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.843 · Cited by 4

Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database

Mian, H. S., LeBlanc, R., Louzada, M., Masih‐Khan, E., McCurdy, A. B. R., Venner, C. P., Stakiw, J., Kardjadj, M., Jimenez-Zepeda, V. H., Sébag, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5245 · Cited by 4

Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma

Abdallah, N. H., & Kumar, S. K. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7039 · Cited by 4

Treatment of elderly and frail myeloma patients.

Shih, S., Visram, A., & Mian, H. (2024) · Presse medicale · doi:10.1016/j.lpm.2024.104266 · Cited by 4

Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience

Shpitzer, D., Cohen, Y. C., Shragai, T., Grossberger, O., Amsterdam, D., Benaim, A. R., & Avivi, I. M. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015968 · Cited by 4

Current status of drug repositioning in hematology

Ohmoto, A., & Fuji, S. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1995348 · Cited by 4

Practical guidance for new multiple myeloma treatment regimens: A nursing perspective

Epstein, M., & Morrison, C. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.010 · Cited by 5

Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone

Kim, S. Y., Park, S., Lim, J., Lee, J. Y., Yoon, J., Lee, S., Eom, K., Kim, H., & Min, C. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.012 · Cited by 4

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience

Furlan, A., Cea, M., Pavan, L., Galli, M., Clissa, C., Mangiacavalli, S., Cafro, A. M., Girlanda, S., Patriarca, F. F., Minotto, C., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7071 · Cited by 4

Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma

LeBlanc, R., Song, K., White, D. J., Christofides, A., & Doucette, S. (2019) · Current Oncology · doi:10.3747/co.26.5565 · Cited by 4

Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma

Ishida, T., Kimura, H., Ozaki, S., Kubo, K., Sunami, K., Takezako, N., Fujita, H., Hayashi, T., Kiguchi, T., Ohashi, K., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03988-6 · Cited by 4

Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis

Giri, S., Barth, P. M., Costa, L. J., & Olszewski, A. J. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.07.007 · Cited by 4

Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients

Gardeney, H., Bobin, A., Gruchet, C., Sabirou, F., Lévy, A., Nsiala, L., Cailly, L., Tomowiak, C., Diaz, J. M. T., Moya, N., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113554 · Cited by 4

SOHO State of the Art Updates and Next Questions: Treatment of Older, Vulnerable Adults with Multiple Myeloma

Grant, S. J., Joshi, G., & Lipe, B. C. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.003 · Cited by 4

Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA

Hari, P., Blazer, M. A., Raju, A., Farrelly, E., Labotka, R., Skácel, T., & Romanus, D. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2019.1555460 · Cited by 4

MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma

Cui, Q.-Q., Li, Z., & Ma, Y. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2358857 · Cited by 3

Real‐World Outcomes of Transplant Ineligible Older Adults With Multiple Myeloma Treated With Novel Regimens: A Population‐Based Retrospective Cohort Study

Abdallah, N. H., Mian, H. S., Seow, H. Y., Pond, G. R., Gayowsky, A., Visram, A., Costa, L. J., Wildes, T. M., Fonseca, R., Pawlyn, C., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70042 · Cited by 3

Treatment of transplant-ineligible multiple myeloma

Jung, J. (2025) · Blood Research · doi:10.1007/s44313-025-00102-5 · Cited by 3

Reshaping multiple myeloma treatment: recent breakthroughs

Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2610373 · Cited by 4

Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients

Horigome, Y., Suzuki, K., & Suzuki, T. (2024) · Life · doi:10.3390/life14030389 · Cited by 3

Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs

Gu, X., Tang, W., Zhang, L., Zheng, Y., Pan, L., & Niu, T. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01445-6 · Cited by 3

Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation

Hu, S.-L., Liu, M., & Zhang, J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i32.11712 · Cited by 3

Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum

Shimura, Y., Shibayama, H., Nakaya, A., Yamamura, R., Imada, K., Kaneko, H., Hanamoto, H., Fuchida, S., Tanaka, H., Kosugi, S., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03653-4 · Cited by 3

Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma

Sharpley, F. A., Djebbari, F., Fourali, S., Kothari, J., Lynes, J. A., McLain-Smith, S., & Ramasamy, K. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1683737 · Cited by 3

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients

Belch, A. R., Bahlis, N. J., White, D. J., Cheung, M. C., Chen, C. I., Shustik, C., Song, K., Tosikyan, A., Dispenzieri, A. A., Anderson, K. C., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3511 · Cited by 3

Perspectives for the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma

Семочкин, С. В. (2023) · Clinical oncohematology · doi:10.21320/2500-2139-2023-16-3-229-241 · Cited by 3

Management of newly diagnosed transplant ineligible multiple myeloma

Atrash, S., Bhutani, M., Paul, B. A., Voorhees, P. M., & Usmani, S. Z. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1786558 · Cited by 3

Management of Multiple Myeloma in Older Patients

Li, J., & Chan, H. S. H. (2021) · EMJ Hematology · doi:10.33590/emjhematol/20-00241 · Cited by 3

Myélome multiple : des critères diagnostiques et pronostiques renouvelés et de forts espoirs thérapeutiques

Manier, S., de la Contrie, M. D. C., Hieulle, J., Daniel, A., & Facon, T. T. F. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.07.023 · Cited by 3

Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial

Bringhen, S., Cani, L., Antonioli, E., Derudas, D., Fazio, F., Larocca, A., Ronconi, S., Cellini, C., Falcone, A. P., Accardi, F., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00162-0 · Cited by 2

Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline

Jenner, M. W., Boyd, K. D., Choudhuri, S., Parrish, C., Garg, M. K., Stern, S., & the British Society of Haematology and UK Myeloma Society (2025) · British Journal of Haematology · doi:10.1111/bjh.70149 · Cited by 2

BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study

Liu, J., Fan, X., Peng, L., Liu, J., He, H.-Y., Qiang, W.-T., Jin, L., Shi, L., Lu, J., Guo, P., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019036 · Cited by 2

Hämatologische Neoplasien und solide Tumore

Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_5 · Cited by 2

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide

Rekhtina, I. G., & Mendeleeva, L. P. (2019) · Oncohematology · doi:10.17650/1818-8346-2019-14-1-8-13 · Cited by 2

Evolution of diagnostic workup and treatment for multiple myeloma 2013‐2019

Schjesvold, F. H. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13464 · Cited by 2

Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia

Oganesyan, A., Ghahramanyan, N., MEKINIAN, A., Bejanyan, N., Kazandjian, D. G., & Hakobyan, Y. K. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.11.003 · Cited by 3

Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity

Sengar, M., Hopman, W. M., Mohyuddin, G. R., Goodman, A. M., Gyawali, B., Mukherji, D., Hammad, N., Pramesh, C. S., Aggarwal, A. K., Sullivan, R. J., et al. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1558 · Cited by 2

At what point are we on the way to optimally treat multiple myeloma patients over 75 years of age in 2023?

Tyczyńska, A., & Zaucha, J. M. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/168685 · Cited by 2

Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?

Mian, H. S., & Wildes, T. M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0539-1 · Cited by 2

Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients

Tacchetti, P., Rocchi, S., Barbato, S., Zamagni, E., Pantani, L., Mancuso, K., Rizzello, I., & Cavo, M. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1983426 · Cited by 2

Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis

Manier, S., Dimopoulos, M. A., Hulin, C., Leleu, X. P., Delforge, M., Weisel, K. C., Mouro, J. L., Costa, B. A., Sturniolo, M., & Facon, T. T. F. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.06.002 · Cited by 2

Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma

O’Meara, K., Fansiwala, K. M., Kathuria‐Prakash, N., El‐Masry, M., & Oh, S. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03129-z · Cited by 2

Ixazomib in the treatment of relapsed multiple myeloma

Семочкин, С. В. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-10-84-91 · Cited by 2

Simplified novel prognostic score for real-life older adults with multiple myeloma—registry-based analysis

Radocha, J., Hájek, R., Brožová, L., Pour, L., Špıčka, I., Minařík, J., Gregora, E., Jungová, A., Jelı́nek, T., Heindorfer, A., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3568-2 · Cited by 2

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

Bahlis, N. J., Corso, A., Mügge, L.-O., Shen, Z.-X., Desjardins, P., Stoppa, A.-M., Decaux, O., de Revel, T., Granell, M., Marit, G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.111 · Cited by 20

Final Analysis of Overall Survival from the First Trial

Facon, T. T. F., Dimopoulos, M. A., Dispenzieri, A. A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K. C., Ludwig, H., Bahlis, N. J., et al. (2016) · Blood · doi:10.1182/blood.v128.22.241.241 · Cited by 13

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Bahlis, N. J., Corso, A., Mügge, L., Shen, Z., Desjardins, P., Stoppa, A., Decaux, O., de Revel, T., Granell, M., Marit, G., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3458.3458 · Cited by 1

PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Belch, A. R., Bahlis, N. J., White, D. J., Cheung, M., Chen, C., Shustik, C., Song, K., Tosikyan, A., Dispenzieri, A. A., Anderson, K. C., et al. (2019) · HemaSphere · doi:10.1097/01.hs9.0000567032.31064.27

Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM)

Facon, T. T. F., Dimopoulos, M. A., Hulin, C., Benboubker, L., Belch, A., Ludwig, H., Pinto, A., Attal, M., Cavo, M., Moreau, P., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.330 · Cited by 5